PDS Biotechnology (PDSB) Files 8-K Furnishing June 2025 Investor Deck

PDS Biotechnology Corporation (NASDAQ: PDSB) filed a Form 8-K on June 25, 2025 under Item 8.01 to announce that it has updated its corporate presentation deck.

Rhea-AI Filing Summary

PDS Biotechnology Corporation (NASDAQ: PDSB) filed a Form 8-K on June 25, 2025 under Item 8.01 to announce that it has updated its corporate presentation deck. The new June 2025 slide deck is furnished as Exhibit 99.1 and incorporated by reference into the filing. No financial statements, earnings figures, strategic transactions, or other material events were disclosed. Investors should review the furnished deck for any updated development timelines or clinical program highlights; however, the 8-K itself contains no additional quantitative or qualitative information.

Insights

Securities Analyst

TL;DR: Administrative 8-K; only furnishes updated investor deck, no new financial or strategic data—neutral market impact.

The filing is limited to Item 8.01, indicating no binding commitments or financial disclosures. While a refreshed presentation can refine messaging and reveal incremental clinical details, those specifics are not included in the 8-K text. Until investors review Exhibit 99.1, the market impact remains neutral. Overall, this is routine investor-relations housekeeping.

Corporate Governance Expert

TL;DR: Routine corporate communication; satisfies disclosure obligations by publicly posting the latest slide deck.

The company fulfills Regulation FD by furnishing the presentation via EDGAR, ensuring equal information access. No board actions, officer changes, or governance shifts are reported. Compliance appears intact, and the event is non-material from a governance-risk perspective.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PDS Biotechnology (PDSB) file on June 25, 2025?

A Form 8-K announcing it has updated its corporate presentation, furnished as Exhibit 99.1.

Does the 8-K include any financial results or guidance?

No. The filing solely references the updated presentation and contains no financial statements or earnings data.

Where can investors access the new PDSB corporate presentation?

The slide deck is available on EDGAR as Exhibit 99.1 to the June 25, 2025 Form 8-K.

Are there any material transactions or management changes disclosed?

No. The 8-K lists no acquisitions, divestitures, executive departures, or board actions.

Why did PDS Biotechnology use Item 8.01 for this disclosure?

Item 8.01 allows companies to furnish information they deem of interest to security holders; here, the updated investor deck.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2025 - 04:06 PM Learn about SEC filing dates

false0001472091NASDAQ00014720912025-06-252025-06-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2025

PDS BIOTECHNOLOGY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37568	26-4231384
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

303A College Road East, Princeton, NJ 08540

(Address of Principal Executive Offices, and Zip Code)

(800) 208-3343

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00033 per share	PDSB	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 8.01 Other Events.

On June 25, 2025, the Company updated its corporate presentation deck.

A copy of the corporate presentation deck is filed herewith as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Corporate Presentation (June 2025).
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PDS BIOTECHNOLOGY CORPORATION
Date:  June 25, 2025	By:	/s/ Frank Bedu-Addo, Ph.D.
	Name: Frank Bedu-Addo, Ph.D.
	Title: President and Chief Executive Officer